





DCB's Bispecific Antibody Platform

- 1. Patent Protection (US, PCT, and TW Patents applied)
- 2. High production yield (Comparable to monoclonal antibody)
- 3. Target cell-dependent T cell activation (Better safety profile)
- 4. Long plasma half-life (Comparing to the fragment BsAb format)
- 5. Low immunogenicity in rat (No detectable ADA with multiple doses injection)






Mechanism of Action






Purity & Heterogeneity Analysis of BsAbs by Non-Reduced CE-SDS



No.	Sample	LC	нс	H+L	2H	2H1L	NG	Intact
1	Asymmetric IgG (Alg)	0.38% (14.817)		0.36% (21.483)	0.55% (23.958)	2.12% (25.708)		96.59% (27.133)
2	Asymmetric IgG-T01 (Alg-T01)	0.22%		0.78% (21.475)		0.81% (26.433)		98.19% (27.617)
3	Asymmetric IgG-T02 (Alg-T02)	0.26%	72	0.42% (23.075)		0.75%		98.57% (27.422)
4	Asymmetric IgG-T03 (Alg-T03)	0.20% (14.858)		2.48% (23.083)		1.51% (27.817)	<u>_657</u>	95.81% (28.425)
		 1						




T Cell Activation and IL-2 Production of PBMC Induced by Anti-Globo H:CD3 BsAb




T Cell-mediated Tumor Cell Cytotoxicity Induced by Anti-Globo H:CD3 BsAb

E: Tratio= T cells : HCC1428-GFP = 20:1 [48-84 hr] with DAPI Asymmetric IgG-T01









Therapeutic Effect of Anti-Globo H:CD3 BsAb in HCC1428 Xenograft Mice

HCC1428 breast cancer cells xenograft animal model in female NOD/SCID mice (Study M09)

Tumor growth was calculated as T/C (treatment/control) x 100%.

 $T/C = (T_n/C_n) \times 100\%$

C_n: Tumor weight measured on Day n in the control group

